![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Université Catholique de Louvain, Louvain-la-Neuve B-1348, Belgium
* To whom correspondence should be addressed. E-mail: marcel{at}fefem.com.
A prebiotic is "a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host well-being and health." Today, only 2 dietary nondigestible oligosaccharides fulfill all the criteria for prebiotic classification. The daily dose of the prebiotic is not a determinant of the prebiotic effect, which is mainly influenced by the number of bifidobacteria/g in feces before supplementation of the diet with the prebiotic begins. The ingested prebiotic stimulates the whole indigenous population of bifidobacteria to growth, and the larger that population, the larger is the number of new bacterial cells appearing in feces. The "dose argument" is thus not supported by the scientific data: it is misleading for consumers and should not be allowed. A prebiotic index is proposed, defined as "the increase in the absolute number of bifidobacteria expressed divided by the daily dose of prebiotic ingested."
This article has been cited by other articles:
|
|
 |
|
  S. Rao, R. Srinivasjois, and S. Patole Prebiotic Supplementation in Full-term Neonates: A Systematic Review of Randomized Controlled Trials Arch Pediatr Adolesc Med, August 1, 2009; 163(8): 755 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pokusaeva, M. O'Connell-Motherway, A. Zomer, G. F. Fitzgerald, and D. van Sinderen Characterization of Two Novel {alpha}-Glucosidases from Bifidobacterium breve UCC2003 Appl. Envir. Microbiol., February 15, 2009; 75(4): 1135 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schouler, A. Taki, I. Chouikha, M. Moulin-Schouleur, and P. Gilot A Genomic Island of an Extraintestinal Pathogenic Escherichia coli Strain Enables the Metabolism of Fructooligosaccharides, Which Improves Intestinal Colonization J. Bacteriol., January 1, 2009; 191(1): 388 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ruggeri, R. Straniero, S. Pacifico, A. Aguzzi, and F. Virgili French Marine Bark Extract Pycnogenol as a Possible Enrichment Ingredient for Yogurt J Dairy Sci, December 1, 2008; 91(12): 4484 - 4491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Hill, H. G. Bateman II, J. M. Aldrich, and R. L. Schlotterbeck Oligosaccharides for Dairy Calves Professional Animal Scientist, October 1, 2008; 24(5): 460 - 464. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Boehm and G. Moro Structural and Functional Aspects of Prebiotics Used in Infant Nutrition J. Nutr., September 1, 2008; 138(9): 1818S - 1828S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gonzalez, E. S. Klaassens, E. Malinen, W. M. de Vos, and E. E. Vaughan Differential Transcriptional Response of Bifidobacterium longum to Human Milk, Formula Milk, and Galactooligosaccharide Appl. Envir. Microbiol., August 1, 2008; 74(15): 4686 - 4694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Depeint, G. Tzortzis, J. Vulevic, K. I'Anson, and G. R Gibson Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study Am. J. Clinical Nutrition, March 1, 2008; 87(3): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
